Ironwood Pharmaceuticals (IRWD) Change in Accured Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$219000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$219000.0, down 102.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.7 million (down 285.86% YoY), and the FY2025 annual result was $6.2 million, up 130.69% from the prior year.
• Change in Accured Expenses came in at -$219000.0 for Q1 2026 at Ironwood Pharmaceuticals, up from -$318000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $20.9 million in Q3 2023 to a low of -$31.6 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $705000.0 (2023), against an average of -$586000.0.
• Peak annual rise in Change in Accured Expenses reached 479.21% in 2024, while the deepest fall reached 1876.74% in 2024.
• Ironwood Pharmaceuticals' Change in Accured Expenses stood at -$2.0 million in 2022, then slumped by 524.85% to -$12.5 million in 2023, then tumbled by 152.06% to -$31.6 million in 2024, then jumped by 98.99% to -$318000.0 in 2025, then jumped by 31.13% to -$219000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$219000.0 (Q1 2026), -$318000.0 (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.